Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study.

ABSTRACT:

Background

Breast cancer is the most common tumor among women worldwide, which human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for approximately 15-20%. Although anti-HER2 agents have already diversified in recent years, a highly effective and more affordable treatment option is urgently needed. Inetetamab is a new antibody exhibiting efficacy in managing HER2-positive advanced breast cancer (ABC) through antibody-dependent cellular cytotoxicity (ADCC). Pyrotinib is a second-line treatment specifically targeting HER2. Given that pyrotinib could exhibit strong HER2 antagonism and synergize with monoclonal antibodies to boost ADCC effect, herein we investigated the effects and safety of first to third line of combined treatments utilizing inetetamab plus vin

SUBMITTER: Jin N 

PROVIDER: S-EPMC12593989 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature